首页> Progress in transplantation (Aliso Viejo, Calif.)> Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.

Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Nicola,de'Angelis

第一单位： 1 Department of HPB Surgery and Liver Transplantation, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France.

作者： Nicola,de'Angelis ^[1] ; Filippo,Landi ^[1] ; Marco,Nencioni ^[1] ; Anais,Palen ^[1] ; Eylon,Lahat ^[1] ; Chady,Salloum ^[1] ; Philippe,Compagnon ^[1] ; Chetana,Lim ^[1] ; Charlotte,Costentin ^[2] ; Julien,Calderaro ^[3] ; Alain,Luciani ^[4] ; Cyrille,Feray ^[5] ; Daniel,Azoulay ^[6]

作者单位： 1 Department of HPB Surgery and Liver Transplantation, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France. ^[1] 2 Department of Hepatology, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France. ^[2] 3 Department of Pathology, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France.;4 INSERM Unit UMR1162, Créteil, France. ^[3] 5 Department of Radiology and Medical Imaging, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France.;6 INSERM Unit 955, Créteil, France. ^[4] 2 Department of Hepatology, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France.;6 INSERM Unit 955, Créteil, France. ^[5] 1 Department of HPB Surgery and Liver Transplantation, Henri-Mondor Hospital, Université Paris Est-UPEC, Créteil, France.;6 INSERM Unit 955, Créteil, France. ^[6]

关键词 best supportive care hepatocellular carcinoma liver transplantation sorafenib tumor recurrence